US Patent 7999114 Dicycloalkylcarbamoyl ureas as glucokinase activators
Patent 7999114 was granted and assigned to Novo Nordisk on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+270 characters)
Article
Patent abstract
This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Anthony Murray0
Jesper Lau0
Lone Jeppesen0
Marit Kristiansen0
Per Vedso0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07999114 Dicycloalkylcarbamoyl ureas as glucokinase activators US Patent 7999114 Dicycloalkylcarbamoyl ureas as glucokinase activators
Infobox
Patent Number
079991140
Patent Number
79991140
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079991140
Date of Patent
August 16, 2011
0Patent Application Number
119947180
Date Filed
July 7, 2006
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07999114 Dicycloalkylcarbamoyl ureas as glucokinase activators
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07999114
Date of patent
August 16, 2011
Patent application number
11994718
Date Filed
July 7, 2006
Patent primary examiner
Find more entities like US Patent 7999114 Dicycloalkylcarbamoyl ureas as glucokinase activators
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
